#USA #New York #securities lawsuit #SueWallSt #Regencell Bio

Legal Action Against Regencell Bioscience Holdings

On June 4, 2026, a significant legal development occurred involving Regencell Bioscience Holdings Limited, a company traded on NASDAQ under the ticker RGC. A securities class action lawsuit has been filed by investors who believe they have suffered losses due to the alleged concealment of critical information regarding the company's operations and stock performance.

Allegations of Misleading Information

The crux of the lawsuit centers around the claim that Regencell's management had been aware that the company's stock was susceptible to market manipulation throughout the class period from October 28, 2024, to October 31, 2025. It is alleged that, despite this awareness, the company failed to disclose important risks to shareholders, which led to significant financial losses when truth was revealed.

What Happened?

The trouble for Regencell began to escalate when the company’s shares experienced a dramatic drop of 18.56%, falling from a closing price of $16.65 to $13.56 on November 3, 2025. This decline followed the announcement of a Department of Justice (DOJ) subpoena investigating the volatility surrounding Regencell's stock trading.

Further investigation by the company revealed a startling lack of foundational support for its staggering market valuation. Regencell had been valued at around $14 billion, despite having zero revenue and only twelve employees on its payroll. The firm's research and development expenditures were also significantly below industry norms, contributing to questions about its operational viability.

The Lead Plaintiff Deadline

Investors have until June 23, 2026, to file a lead plaintiff application to join the class action. Time is of the essence for those who purchased shares during the specified period, as they may be eligible to recover losses incurred as a result of the alleged mismanagement and misinformation.

Green Flags Raised

The lawsuit raises several red flags that suggest the company's business practices were questionable:

• - Stock Performance: Regencell's stock price experienced extraordinary fluctuations, including a 48,650% increase to $78.00 from its previous trading levels under $1.00 per share.
• - Business Fundamentals: The absence of approved products, revenue generation, and a comparably low number of employees heightened scrutiny over its business practices.
• - Market Activity: After a stock split of 38-for-1 in June 2025, the stock exhibited extreme volatility, with daily trading ranges indicating potential external manipulation rather than a reflection of the company's financial health. The SEC later attributed some of this volatility to market activity from short sellers and social media buzz but did not address deeper underlying issues that the lawsuit alleges were deliberately overlooked by management.

Transparency Issues

The complaint contends there is a stark difference between the representations made by Regencell’s executives and the reality of its financial condition. Insiders were reportedly aware of these contradictions long before public disclosures indicated any issue. The Sarbanes-Oxley certifications signed by the company's leadership are called into question, suggesting they may not fully comply with the truthfulness expected in SEC filings regarding the potential for substantial regulatory scrutiny due to market manipulation risks.

While the annual report on October 31, 2025, did disclose the DOJ subpoena, it raised new concerns about possible regulatory repercussions, including fines and penalties. This disclosure followed a prolonged period during which investors were potentially left uninformed about critical risks.

What Investors Should Do Now

For shareholders who are concerned about their investment in Regencell, it is crucial to document and gather all relevant information, including purchase dates, numbers of shares, and prices paid while investing to aid in any potential claims. They can reach out to SueWallSt via email at [email protected] or through the dedicated hotline at (888) SueWallSt for guidance on this class action suit. Importantly, participation in the class action presents no upfront costs, as these cases are typically pursued on a contingency basis, meaning legal fees are only collected if there is a successful recovery.

Conclusion

The unfolding lawsuit serves as a crucial reminder for investors to remain vigilant and informed about the businesses in which they invest. The outcome of the case against Regencell could potentially lead to significant recoveries for affected shareholders and a necessary reevaluation of corporate governance practices within the company.

Investors impacted by this situation are encouraged to act swiftly to ensure their rights are protected before deadlines lapse.